GRI:NSD-GRI Bio Inc. (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.58

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.02B

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 125.13B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 111.91B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 37.99B
ARGX argenx NV ADR

N/A

USD 33.78B
BGNE BeiGene Ltd

N/A

USD 26.57B
MRNA Moderna Inc

N/A

USD 21.07B
RPRX Royalty Pharma Plc

N/A

USD 16.63B
UTHR United Therapeutics Corporatio..

N/A

USD 16.00B
SMMT Summit Therapeutics PLC

N/A

USD 14.66B
PCVX Vaxcyte Inc

N/A

USD 14.16B

ETFs Containing GRI

UKPH:XETRA iShares UK Property UCITS.. 3.23 % 0.00 %

N/A

N/A
UKRE:LSE iShares MSCI Target UK Re.. 0.00 % 0.00 %

N/A

USD 0.12B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 50.65% 54% F 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.65% 54% F 76% C+
Trailing 12 Months  
Capital Gain -49.57% 12% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -49.57% 12% F 14% F
Trailing 5 Years  
Capital Gain -98.83% 2% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.83% 2% F 1% F
Average Annual (5 Year Horizon)  
Capital Gain -31.30% 13% F 7% C-
Dividend Return -31.30% 13% F 7% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 45.56% 68% D+ 40% F
Risk Adjusted Return -68.69% 17% F 11% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector